Wikipedia Disease Information Worth Monitoring By Pharma Companies, IMS Says
An analysis of Wikipedia page visits over the last two years shows that rarer diseases had a higher frequency of visits than many more common conditions, IMS Institute for Health Informatics says.
You may also be interested in...
The draft guidance outlines substantial reporting requirements for websites that firms control and for content on third-party sites – as well as saying when FDA intends to use enforcement discretion.
Drug makers are using YouTube videos and other social media channels to broadcast their expertise and initiatives; Amgen differentiates its biologic manufacturing from biosimilars, J&J teams up with Huffington Post to tell stories about motherhood, and Pfizer tries to conduct a clinical trial online.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.